Brexpiprazole Powder CAS 5118-13-8
Adenine Brexpiprazole
Brand Nutrabiotech
4-Bromobenzo[b]thiophene
CAS No. 5118-13-8
Molecular weight 213.09
Molecular Formula C8H5BrS
Synonyms Brexpiprazole;OPC-34712;7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone;7-[4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one;7-[4-(4-(Benzo[b]thien-4-yl)-piperazin-1-yl)butoxy]-1H-quinolin-2-one
Brexpiprazole is an atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
High doses or long-term use of brexpiprazole can cause a serious movement disorder that may not be reversible. Symptoms of this disorder include uncontrollable muscle movements of your lips, tongue, eyes, face, arms, or legs. The longer you take brexpiprazole, the more likely you are to develop a serious movement disorder. The risk of this side effect is higher in women and older adults.